内分泌科

订阅

MedSci主页 / 所有栏目 / 内分泌科

DIABETOLOGIA：转录因子STAT6在促进β细胞存活方面起着关键作用

2019-04-04 不详 网络

β细胞存活糖尿病
关注

<span style="font-size:12.0pt;font-family:宋体;mso-ascii-font-family: Calibri;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:宋体;mso-fareast-theme-font: minor-fareast;mso-hansi-font-family:Ca

在1型糖尿病中，在炎症性胰岛环境中选择性β细胞丢失发生。这种环境是通过促炎细胞因子的增强分泌和IL-4和IL-13等抗炎分子的丢失而产生的。虽然促炎细胞因子的作用已经在β细胞中得到了很好的研究，但它们的抗炎作用相对较少受到关注。

研究人员克隆β细胞、分离的人胰岛和来自对照个体和1型糖尿病患者的胰腺切片。采用靶向基因芯片和定量RT-PCR检测基因表达。用免疫细胞化学方法检测蛋白在细胞提取物和组织切片中的表达。用干扰RNA选择性地敲除靶蛋白。

结果显示，IL-4和IL-13的细胞保护作用是通过信号传感器的早期激活和β细胞转录因子6 (STAT6)的激活来实现的，从而导致抗凋亡蛋白的上调，包括髓样白血病(mcl1)和B细胞淋巴瘤(BCLXL)。我们也报告的感应信号监管protein-α(SIRPα),并发现敲除SIRPα与β细胞生存能力降低有关。这些抗凋亡蛋白及其伴随的细胞保护作用在sirna介导的下调STAT6后丢失。重要的是，对人类胰腺切片的分析显示，1型糖尿病患者的β细胞中STAT6明显减少，这意味着细胞保护反应的丧失。

研究表明，STAT6的选择性缺失可能在1型糖尿病进展过程中导致β细胞死亡

原始出处：

Kaiyven A. Leslie, Mark A. The transcription factor STAT6 plays a critical role in promoting beta cell viability and is depleted in islets of individuals with type 1 diabetes

本文系梅斯医学（MedSci）原创编译整理，转载需授权！


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1639061, encodeId=8b9d1639061ce, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Sep 20 02:43:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747351, encodeId=b65c1e4735179, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Jun 08 06:43:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761072, encodeId=46331e6107269, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Feb 06 19:43:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537487, encodeId=32f6153e4870a, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Sat Apr 06 12:43:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618908, encodeId=3f581618908f3, content=<a href='/topic/show?id=007419239ca' target=_blank style='color:#2F92EE;'>#β细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19239, encryptionId=007419239ca, topicName=β细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b69919964433, createdName=ms24272190615788285182, createdTime=Sat Apr 06 12:43:00 CST 2019, time=2019-04-06, status=1, ipAttribution=)]
    2019-09-20 ms9608593228839890

    #DIA#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1639061, encodeId=8b9d1639061ce, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Sep 20 02:43:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747351, encodeId=b65c1e4735179, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Jun 08 06:43:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761072, encodeId=46331e6107269, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Feb 06 19:43:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537487, encodeId=32f6153e4870a, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Sat Apr 06 12:43:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618908, encodeId=3f581618908f3, content=<a href='/topic/show?id=007419239ca' target=_blank style='color:#2F92EE;'>#β细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19239, encryptionId=007419239ca, topicName=β细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b69919964433, createdName=ms24272190615788285182, createdTime=Sat Apr 06 12:43:00 CST 2019, time=2019-04-06, status=1, ipAttribution=)]
    2019-06-08 mjldent

    #转录#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1639061, encodeId=8b9d1639061ce, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Sep 20 02:43:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747351, encodeId=b65c1e4735179, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Jun 08 06:43:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761072, encodeId=46331e6107269, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Feb 06 19:43:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537487, encodeId=32f6153e4870a, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Sat Apr 06 12:43:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618908, encodeId=3f581618908f3, content=<a href='/topic/show?id=007419239ca' target=_blank style='color:#2F92EE;'>#β细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19239, encryptionId=007419239ca, topicName=β细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b69919964433, createdName=ms24272190615788285182, createdTime=Sat Apr 06 12:43:00 CST 2019, time=2019-04-06, status=1, ipAttribution=)]
    2020-02-06 ms5439512287675881

    #BET#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1639061, encodeId=8b9d1639061ce, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Sep 20 02:43:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747351, encodeId=b65c1e4735179, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Jun 08 06:43:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761072, encodeId=46331e6107269, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Feb 06 19:43:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537487, encodeId=32f6153e4870a, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Sat Apr 06 12:43:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618908, encodeId=3f581618908f3, content=<a href='/topic/show?id=007419239ca' target=_blank style='color:#2F92EE;'>#β细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19239, encryptionId=007419239ca, topicName=β细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b69919964433, createdName=ms24272190615788285182, createdTime=Sat Apr 06 12:43:00 CST 2019, time=2019-04-06, status=1, ipAttribution=)]
    2019-04-06 lanyan20020090

    #转录因子#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1639061, encodeId=8b9d1639061ce, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Fri Sep 20 02:43:00 CST 2019, time=2019-09-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747351, encodeId=b65c1e4735179, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Sat Jun 08 06:43:00 CST 2019, time=2019-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1761072, encodeId=46331e6107269, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Thu Feb 06 19:43:00 CST 2020, time=2020-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537487, encodeId=32f6153e4870a, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Sat Apr 06 12:43:00 CST 2019, time=2019-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618908, encodeId=3f581618908f3, content=<a href='/topic/show?id=007419239ca' target=_blank style='color:#2F92EE;'>#β细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19239, encryptionId=007419239ca, topicName=β细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b69919964433, createdName=ms24272190615788285182, createdTime=Sat Apr 06 12:43:00 CST 2019, time=2019-04-06, status=1, ipAttribution=)]
    2019-04-06 ms24272190615788285182

    #β细胞#

    0

相关资讯

Diabetes Obes Metab：DPP-4抑制剂不对β细胞功能造成影响

根据12月11日在糖尿病，肥胖和代谢上发表的一项研究，对于健康的成年人和2型糖尿病（T2D）控制良好的个体而言，单剂量的二肽基肽酶-4抑制剂西格列汀与标准化胰岛素分泌增加相关，而对β细胞葡萄糖敏感性没有影响。

Diabetes：胰腺α细胞和β细胞增殖需要p300/CBP转录共激活。

p300（EP300）和CBP（CREBBP）转录共激活，具有组蛋白乙酰转移酶活性。已观察到多种β细胞转录因子可招募p300/CBP，因此，研究人员推测，该共激活剂可能对活体内β细胞发挥正常功能起着重要的作用。Chi Kin Wong等人猜测p300/CBP可促进胰腺的发育，维持胰腺的正常功能。研究人员利用缺乏p300/CBP的小鼠来验证上述猜测。胰腺缺乏p300或CBP的小鼠会出现胰腺分泌功能受

Diabetes：促进β细胞增殖 为糖尿病治疗提供新希望

糖尿病主要包括因自身免疫系统失调导致的1型糖尿病和因胰岛素抵抗或胰岛素分泌不足导致的2型糖尿病两种主要类型。对于这两类病人来说，能够增加β细胞量的治疗方法都对糖尿病治疗大有益处。

Stem Cell Rep：干细胞能逆转糖尿病吗？

对于糖尿病患者来说，通过恰当的护理方法可以控制住病情，但目前还没有彻底治愈的方法。一些科学家认为，将干细胞转化为分泌胰岛素的细胞或许能带来治愈糖尿病的希望。

Diabetologia：前瞻性代谢和胰岛细胞评估（PROMISE）队列中NEFA组成与胰岛素敏感性和β细胞功能的关联

近日，国际杂志 《Diabetologia》上在线发表一项关于前瞻性代谢和胰岛细胞评估（PROMISE）队列中NEFA组成与胰岛素敏感性和β细胞功能的关联的研究。研究人员的目标是确定单个NEFA与糖尿病发病机制的纵向联系，特别是在具有糖尿病风险的个体队列中6年以上的胰岛素敏感性和β细胞功能的差异。 在前瞻性代谢和胰岛细胞评估（PROMISE）纵向队列中，对477名参与者在基线访视时测量了血清

Diabetes：IL-6可通过将自噬与抗氧化反应相偶联从而减少β细胞氧化应激损伤

活性氧（ROS）产生是糖尿病β细胞功能障碍的关键因素。既往研究表明，多效性的细胞因子IL-6与β细胞自噬相关，但IL-6是否影响β细胞的氧化应激尚不明确。Michelle R. Marasco等人利用糖尿病小鼠模型、体外培养的人类胰岛和啮齿动物的β细胞来研究IL-6是否影响氧化应激反应。结果显示IL-6偶联自噬抗氧化应激，可减少β细胞和人类胰岛的ROS。在活体内，β细胞特异性丧失IL-6信号使小鼠